Propanc Biopharma, Inc.
PPCB · NASDAQ
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Market Cap | $16,468 | $111 | $810 | $0 |
| - Cash | $12 | $21 | $10 | $4 |
| + Debt | $1,727 | $948 | $546 | $1,041 |
| Enterprise Value | $18,183 | $1,038 | $1,346 | $1,036 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$22 | -$18 | -$6 |
| % Margin | – | – | – | – |
| EBITDA | -$58,339 | -$1,262 | -$2,235 | -$2,139 |
| % Margin | – | – | – | – |
| Net Income | -$58,923 | -$1,821 | -$2,661 | -$2,658 |
| % Margin | – | – | – | – |
| EPS Diluted | -14.85 | -1,200 | -31,268.39 | -1,119,475.67 |
| % Growth | 98.8% | 96.2% | 97.2% | – |
| Operating Cash Flow | -$405 | -$935 | -$1,105 | -$1,436 |
| Capital Expenditures | $0 | -$0 | $0 | $0 |
| Free Cash Flow | -$405 | -$935 | -$1,105 | -$1,436 |